News >

O'Brien Covers Evolution of Ibrutinib in CLL

Gina Columbus @ginacolumbusonc
Published: Tuesday, Feb 13, 2018

Susan M. O’Brien, MD
Susan M. O'Brien, MD
Ibrutinib (Imbruvica) has played an important role in the development of treatment for patients with chronic lymphocytic leukemia (CLL), and long-term follow-up of the RESONATE and RESONATE-2 studies are evidence of the long-lasting responses with the BTK inhibitor.

, O’Brien, discussed the tremendous impact that has been seen with ibrutinib following the long-term follow-up of the RESONATE studies and highlights where this regimen is headed in the future of treatment for patients with CLL.

OncLive: Can you discuss the long-term data that we have seen with the resonate and RESONATE-2 trials?

O’Brien: We now have 4-year follow-up from the original RESONATE study. That was the randomized trial of ibrutinib versus ofatumumab in relapsed patients, which led to the full approval of ibrutinib. We have seen very good data. The important message from this study is that responses can be very durable and that toxicity does not increase over time.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x